Recap: Corcept Therapeutics Q4 Earnings
Corcept Therapeutics (NASDAQ:CORT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Corcept Therapeutics Reports Prelim. Results Of Previously-Announced Tender Offer For Up To 10M Shares Of Co. Stock Between $20.75-$23.75/Share In Cash
Corcept Therapeutics Incorporated (NASDAQ:CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by
Corcept Therapeutics Announces Waiver Of Condition To Its Tender Offer For Common Shares
Corcept Therapeutics Incorporated (NASDAQ:CORT) ("Corcept"), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by
35 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options to maximize shareholder value, including potential merger or acquisition.
Corcept Therapeutics Q3 Adj. EPS $0.30 Beats $0.20 Estimate, Sales $96.10M Miss $97.19M Estimate
Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.20 by 50 percent. This is a 25 percent increase over earnings of $0.24 per share from the
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.